Disagree. I think the business model of taking topical generics to market is low risk and financially rewarding. Unless you wanted to wait 6-8 years and keep tipping in money on the hope that we will have a product? With the generic pipeline we can expect cash flow next year. I am guessing you don't read or listen to the updates?
(20min delay)